| Compound | Follistatin 344 |
|---|---|
| Category | Myostatin-binding protein |
| Class | Growth Hormone and Growth Factors |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Follistatin 344 is catalogued here as a myostatin-binding protein and graded at the "Preclinical" evidence tier. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A naturally occurring glycoprotein that binds and neutralizes myostatin and activin, discussed in muscle-growth contexts. The 344 isoform circulates in research-product form without any human trials.
Mechanism of Action
Follistatin neutralizes TGF-beta family ligands including myostatin; in animal models (including follistatin-gene-therapy studies in primates) increased muscle growth results.
Research and Evidence
Evidence is from animal models and gene-therapy experiments. No trials of the injected 344 isoform in humans exist.
Safety and Side Effects
No human safety data; systemic activin/myostatin blockade has plausible vascular and reproductive effects based on related drug programs.
Frequently Asked Questions
What is the evidence tier of Follistatin 344?
Follistatin 344 is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is Follistatin 344 an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Follistatin 344?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for follistatin studies. [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.